Study in Non-Clear Cell Renal Carcinoma (Ncc-RCC) Temsirolimus Versus Sunitinib

NCT00979966 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

22

Enrollment

OTHER

Sponsor class

Conditions

Non-clear Cell Renal Cell Cancer

Interventions

DRUG: Temsirolimus
DRUG: Sunitinib

Sponsor

Central European Society for Anticancer Drug Research